News

Wheeler will succeed Gerard Barba, who will continue his work as the chairman of the board of directors Before joining Marken, Wheeler served as the president and CEO

An analysis of the weight loss dietary supplement by the FDA found that the product contains undeclared Sibutramine, not approved by the agency, and therefore the safety and

The FDA’s decision allows the company to start a Phase 1 clinical trial of PWT33597, a proprietary, selective, dual inhibitor of PI3K kinase alpha and mTOR. The Phase

Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma. The study evaluated the safety and efficacy of avanafil as a treatment of

Under the agreement, Gallus is acquiring several Xcellerex bioproduction systems for new suites and laboratories at its existing manufacturing facility. The strategic collaboration will provide Gallus with manufacturing

The company expects to enroll around 110 healthy subjects. The study expects to evaluate whether Matrix M is safe and improves the effect on elderly people, due to

CEN-209 is selectively activated in areas of low oxygen often found within solid tumors. Auckland Cancer Society Research Centre (ACSRC) professor William Wilson and associate professor Michael Hay,

The lawsuit was filed in connection with Glenmark‘s submission of an abbreviated new drug application (ANDA) for 0.1% hydrocortisone butyrate cream, Glenmark’s generic version of Locoid Lipocream. As

In the study, the patients will be randomized to either certolizumab pegol plus methotrexate (MTX) or adalimumab plus MTX for 12 weeks. Following this, the patients who will